ClinConnect ClinConnect Logo
Search / Trial NCT00001094

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of May 10, 2025

Withdrawn

Keywords

Hiv 1 Drug Therapy, Combination Zidovudine Lamivudine Rna, Viral Saquinavir Delavirdine Anti Hiv Agents Nelfinavir

ClinConnect Summary

Past studies have shown that combination therapies not only will result in better clinical outcomes but may prolong the effects of therapy. The enhanced effects seen with combination therapies are likely related to a greater suppression of HIV replication and alterations in resistance patterns. Both in vitro and in vivo studies suggest that triple-drug therapy may have an advantage over one- and two-drug regimens. Therefore, triple-drug therapy appears to be an important strategy in the treatment of HIV infection.

This is a Phase II, randomized, controlled, open-label trial of NFV + SQVsgc...

Gender

ALL

Eligibility criteria

  • This study has been terminated.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Columbus, Ohio, United States

New York, New York, United States

Stanford, California, United States

Miami, Florida, United States

Honolulu, Hawaii, United States

Honolulu, Hawaii, United States

Chicago, Illinois, United States

Buffalo, New York, United States

Greensboro, North Carolina, United States

Cincinnati, Ohio, United States

Galveston, Texas, United States

San Juan, , Puerto Rico

Charlotte, North Carolina, United States

New Orleans, Louisiana, United States

Denver, Colorado, United States

Atlanta, Georgia, United States

Menlo Park, California, United States

Patients applied

0 patients applied

Trial Officials

Fischl M

Study Chair

Bartlett J

Study Chair

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials